Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)
Sanofi to pay $2.9B for Provention Bio and its diabetes-delaying drug Tzield
Sanofi and Provention Bio have made a $2.9 billion deal for the French drugmaker to acquire the biotech, which last year won approval for its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
